These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Rhinovirus-induced VP1-specific Antibodies are Group-specific and Associated With Severity of Respiratory Symptoms. Niespodziana K; Cabauatan CR; Jackson DJ; Gallerano D; Trujillo-Torralbo B; Del Rosario A; Mallia P; Valenta R; Johnston SL EBioMedicine; 2015 Jan; 2(1):64-70. PubMed ID: 26137535 [TBL] [Abstract][Full Text] [Related]
7. Overview of human rhinovirus immunogenic epitopes for rational vaccine design. Stepanova E; Isakova-Sivak I; Rudenko L Expert Rev Vaccines; 2019 Sep; 18(9):877-880. PubMed ID: 31416365 [No Abstract] [Full Text] [Related]
8. Immunodominant T-Cell Epitopes in the VP1 Capsid Protein of Rhinovirus Species A and C. Gaido CM; Stone S; Chopra A; Thomas WR; Le Souëf PN; Hales BJ J Virol; 2016 Dec; 90(23):10459-10471. PubMed ID: 27630239 [TBL] [Abstract][Full Text] [Related]
9. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. Katpally U; Fu TM; Freed DC; Casimiro DR; Smith TJ J Virol; 2009 Jul; 83(14):7040-8. PubMed ID: 19403680 [TBL] [Abstract][Full Text] [Related]
10. Identification of Epitopes on Rhinovirus 89 Capsid Proteins Capable of Inducing Neutralizing Antibodies. Niespodziana K; Cabauatan CR; Pazderova P; Vacal PC; Wortmann J; Keller W; Errhalt P; Valenta R Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563505 [TBL] [Abstract][Full Text] [Related]
11. Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections. Niespodziana K; Napora K; Cabauatan C; Focke-Tejkl M; Keller W; Niederberger V; Tsolia M; Christodoulou I; Papadopoulos NG; Valenta R FASEB J; 2012 Mar; 26(3):1001-8. PubMed ID: 22121050 [TBL] [Abstract][Full Text] [Related]
12. Myristoylated rhinovirus VP4 protein activates TLR2-dependent proinflammatory gene expression. Bentley JK; Han M; Jaipalli S; Hinde JL; Lei J; Ishikawa T; Goldsmith AM; Rajput C; Hershenson MB Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L57-L70. PubMed ID: 30908938 [TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643 [TBL] [Abstract][Full Text] [Related]
14. Characterization of Conserved and Promiscuous Human Rhinovirus CD4 T Cell Epitopes. Gomez-Perosanz M; Fiyouzi T; Fernandez-Arquero M; Sidney J; Sette A; Reinherz EL; Lafuente EM; Reche PA Cells; 2021 Sep; 10(9):. PubMed ID: 34571943 [TBL] [Abstract][Full Text] [Related]
15. Mutations at the conserved N-Terminal of the human Rhinovirus capsid gene VP4, and their impact on the immune response. Naeem A; Alkadi HS; Manzoor MU; Yousaf I; Awadalla M; Alturaiki W; AlYami AS; Zafar A; Alosaimi B J Immunoassay Immunochem; 2024 May; 45(3):271-291. PubMed ID: 38551181 [TBL] [Abstract][Full Text] [Related]
16. The conserved N-terminus of human rhinovirus capsid protein VP4 contains membrane pore-forming activity and is a target for neutralizing antibodies. Panjwani A; Asfor AS; Tuthill TJ J Gen Virol; 2016 Dec; 97(12):3238-3242. PubMed ID: 27902347 [TBL] [Abstract][Full Text] [Related]
18. Modeling of the human rhinovirus C capsid suggests a novel topography with insights on receptor preference and immunogenicity. Basta HA; Sgro JY; Palmenberg AC Virology; 2014 Jan; 448():176-84. PubMed ID: 24314648 [TBL] [Abstract][Full Text] [Related]
19. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination. Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410 [TBL] [Abstract][Full Text] [Related]
20. A neutralizing epitope on human rhinovirus type 2 includes amino acid residues between 153 and 164 of virus capsid protein VP2. Skern T; Neubauer C; Frasel L; Gründler P; Sommergruber W; Zorn M; Kuechler E; Blaas D J Gen Virol; 1987 Feb; 68 ( Pt 2)():315-23. PubMed ID: 2434607 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]